Licensing Opportunities

Multiple Technologies and Programs Available for Out-License

Ligand currently has multiple unpartnered programs available for out-licensing in addition to our Captisol, OmniAb, LTP and HepDirect technologies which are available to partners that could benefit from formulation, antibody discovery or other early stage drug targeting and development expertise.

Licensing Opportunities To discuss licensing opportunities, please contact our Business Development Team

Glucagon Receptor Antagonist (GRA)

Summary

Prevalence of diabetes mellitus and obesity has been increasing at an alarming rate despite the availability of many medications and the advancement of medical science. Ligand’s metabolic pathway programs offer unique opportunities to address unmet medical needs and include GRA (progressing to phase 2) and Liver-Specific Glucokinase Activator (GKA) (Research).

More about this opportunity »

Granulocyte Colony Stimulating Factor (GCSF)

Summary

Granulocyte colony stimulating factor (GCSF) acts on its receptor to stimulate the differentiation of bone marrow hematopoietic cells to form neutrophils.

More about this opportunity »

Captisol Enabled™ Busulfan

Summary

Ligand is developing a novel Captisol® formulation of Busulfan for use as a conditioning agent prior to hematopoietic stem cell transplantation.

More about this opportunity »

Captisol-enabled™ Sertraline, Oral Concentrate

Summary

Captisol-enabled® Sertraline (LGD-953) is designed to be the potential first aqueous oral solution to meet the growing demand for better liquid antidepressants for elderly and pediatric patients who are the least able to ingest pills.

More about this opportunity »

Captisol-enabled™ Cetirizine Injection

Summary

Ligand is developing a Captisol-enabled™ injectable formulation of the antihistamine cetirizine to provide rapid onset to treat acute, life-threatening, allergy symptoms.

More about this opportunity »

Captisol-enabled™ Silymarin for Topical Formulation

Summary

Ligand is developing novel Captisol-enabled™ silymarin composition for application in the topical sun damage and anti‐aging premium skin-care markets. 

More about this opportunity »

FLT3 Kinase Inhibitors

Summary

FMS-like tyrosine kinase-3 (FLT3) is a receptor tyrosine kinase with an important role in hematopoietic progenitor cell development.

More about this opportunity »

Liver-Specific Glucokinase Program

Summary

Glucokinase (GKA) is an enzyme that facilitates removal of glucose in circulation and functions as a glucose sensor mainly in the liver and pancreas cells.

More about this opportunity »

CCR1

Summary

Chemokine receptor 1 (CCR1) is a receptor on the surface of various immune cells (e.g. monocytes and T-cells) that bind multiple chemokines and directly mediates inflammatory responses through leukocyte chemotaxis and cytokine balance.

More about this opportunity »